Skip to Content

Alofisel (darvadstrocel) – Withdrawal from EU market

19/12/2024
Medicines for human use Product information update (PIU)

This update is to inform healthcare professionals about the withdrawal of Alofisel (darvadstrocel) from the EU market.

Please see the document inked below for further information.

Product information

Active substance
Expanded human allogeneic mesenchymal adult stem
Authorisation holder
Takeda Pharma A/S
Authorisation number

EU/1/17/1261/001

Human or veterinary medicine
Human medicine 

Documents

Opens in new window Alofisel (darvadstrocel) – Product Information Update – December 2024 PDF : 280KB | 19/12/2024